Skip to Main content Skip to Navigation
Journal articles

Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies.

Abstract : OBJECTIVE: Anti-Hu antibodies (Hu-Ab) and anti-CV2/CRMP5 antibodies (CV2/CRMP5-Ab) have been identified in association with paraneoplastic neurological disorders. However, it is not clear whether these antibodies are associated with specific neurological symptoms or are only markers of anti-cancer immune reaction. METHODS: To address this question, 37 patients with CV2/CRMP5-Ab and 324 patients with Hu-Ab were compared. RESULTS: Whereas the age and sex ratio were the same between the two groups, the distribution of neurological symptoms was not. Patients with CV2/CRMP5-Ab presented more frequently cerebellar ataxia, chorea, uveo/retinal symptoms and myasthenic syndrome (Lambert-Eaton myasthenic syndrome LEMS or myasthenia gravis). They also had a better Rankin score. In contrast, dysautonomia, brainstem encephalitis and peripheral neuropathy were more frequent in patients with Hu-Ab. Limbic encephalitis occurred similarly in both groups. Small-cell lung cancer was the most frequently associated tumour in both groups of patients, while malignant thymoma was observed only in patients with CV2/CRMP5-Ab. In particular, patients with CV2/CRMP5-Ab and thymoma developed myasthenic syndrome more frequently, while patients with SCLC developed neuropathies more frequently. Chorea and myasthenic syndrome were only seen in patients with CV2/CRMP5-Ab. The median survival time was significantly longer in patients with CV2/CRMP5-Ab, and this effect was not dependent on the type of tumour. Interpretation: The data demonstrate that in patients with paraneoplastic neurological syndromes, the neurological symptoms and survival vary with both the type of associated onco-neural antibody and the type of tumour.
Document type :
Journal articles
Complete list of metadatas

https://www.hal.inserm.fr/inserm-00321230
Contributor : Véronique Rogemond <>
Submitted on : Thursday, October 23, 2008 - 9:22:47 AM
Last modification on : Wednesday, August 19, 2020 - 11:18:03 AM
Long-term archiving on: : Tuesday, September 18, 2012 - 12:16:17 PM

Files

Honnorat_et_al_.pdf
Files produced by the author(s)

Identifiers

Collections

Citation

Jérôme Honnorat, Stéphanie Cartalat-Carel, Damien Ricard, Jean-Philippe Camdessanche, Antoine Carpentier, et al.. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies.. Journal of Neurology, Neurosurgery and Psychiatry, BMJ Publishing Group, 2009, 80 (4), pp.412-6. ⟨10.1136/jnnp.2007.138016⟩. ⟨inserm-00321230⟩

Share

Metrics

Record views

1064

Files downloads

2395